Daiichi Sankyo (TSE: 4568) reported preliminary clinical results for DS-3939, an experimental antibody drug conjugate targeting tumor-associated mucin-1, in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE